MK-4827 (Niraparib) , 98% , 1038915-60-4
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB719.20 | In Stock |
|
| 50MG | RMB1375.20 | In Stock |
|
| 100MG | RMB2748.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 187-189°C |
| Boiling point: | 463.6±45.0 °C(Predicted) |
| Density | 1.34 |
| storage temp. | 2-8°C(protect from light) |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 15.36±0.30(Predicted) |
| form | Solid |
| color | Pale Yellow to Light Yellow |
Description and Uses
(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide is also known as MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 (The poly(ADP-ribose) polymerase) with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It has been recently approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death.
Niraparib is a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H332-H335 |
| Precautionary statements | P261-P280-P305+P351+P338 |
